Proven Intelligence in Regulatory Bioanalytics.

A successful Investigational Medicinal Product Dossier (IMPD) for an Advanced Therapy Medicinal Product (ATMP) requires a bioanalytical package that is scientifically robust and tailored to the specific therapeutic modality. Standardized assay panels are insufficient for characterizing the complex biology of AAV vectors, RNA payloads, or cell-based constructs. The strategy for a successful submission centers on developing custom, phase-appropriate bioanalytical methods designed to meet European regulatory expectations, minimize clinical risk, and support an accelerated path to first-in-human studies.

Frequently Asked Questions

Q: What are the key bioanalytical components required for an ATMP IMPD submission to European regulators?

A comprehensive IMPD bioanalytical package must include validated, modality-specific assays for pharmacokinetics (PK), biodistribution, immunogenicity, and potency. This includes methods for vector quantification, transgene expression analysis, and anti-drug antibody (ADA) responses in relevant biological matrices, all performed within a GxP-compliant framework.

Q: How does Franklin Biolabs ensure assays are suitable for next-generation therapies like LNP-delivered RNA or novel AAV capsids?

We develop and qualify custom assays from the ground up, moving beyond generic kits. For instance, we can build species-specific mass spectrometry methods to quantify protein expression directly in tissue, providing definitive proof of biological activity. This tailored approach is necessary for accurately characterizing novel vectors and payloads for which off-the-shelf solutions do not exist.

Q: What is the typical timeline for developing a bioanalytical package to support an IMPD submission?

Aligning bioanalytical development with preclinical toxicology programs allows for an 18-24 month timeline to IND or IMPD readiness. This integrated strategy, supported by our team’s extensive history, has contributed to a 100% successful IND rate since 2019, a track record established by our core scientific leadership prior to the formal launch of Franklin Biolabs in 2024.

Tailored Bioanalytical Strategy for Regulatory Success

A one-size-fits-all preclinical testing template does not exist for ATMPs. The bioanalytical strategy must be adapted to the specific vector, payload, and target indication. An IMPD submission for an AAV9-based therapy targeting the central nervous system will have fundamentally different bioanalytical requirements than an LNP-based siRNA therapeutic for a hepatic disease.

The objective is to build a data package that prospectively answers regulatory questions on mechanism of action, biodistribution, and potential immunogenicity. This requires developing assays with sufficient sensitivity and specificity to characterize the therapeutic in complex biological samples.

Quantifying Transgene Expression and Efficacy

Regulators require definitive evidence that the therapeutic is biologically active. This involves developing custom assays to measure transgene expression and downstream functional outcomes. A key translational challenge is quantifying the expression of a delivered human protein in a nonhuman primate model. Our work has included developing highly specific mass spectrometry methods to measure human frataxin protein in NHP heart tissue, demonstrating that the AAV-delivered payload produces the intended protein in a dose-responsive manner (PMID: 37891254).

Demonstrating a therapeutic effect in a relevant disease model is equally important. In models of familial hypercholesterolemia, AAV8-mediated gene transfer has been shown to not only reduce cholesterol but also induce significant regression of atherosclerosis (PMID: 20976059). This level of data provides strong support for the therapeutic hypothesis within the IMPD.

GxP-Compliant Infrastructure and Integrated Timelines

All custom assay development, qualification, and validation activities are performed in a phase-appropriate manner compliant with GxP guidelines. Our bioanalytical laboratories are co-located with our preclinical facilities, which span over 100,000 sq ft of specialized laboratory and housing space [FBL-VID-06]. This integration allows for rapid sample transfer and analysis, preserving sample integrity and aligning bioanalytical data generation directly with the in-life portion of IND-enabling toxicology studies.

This integrated approach is a core component of our scientific services, which are detailed further on our main Vector | CMC | Analytics Services page. By aligning these functions, programs can move efficiently toward regulatory submission.